Beijing Hope Pharmaceutical Co., Ltd.

This study aimed to study the pharmacokinetic characteristics of a single fasting oral dose of minocycline hydrochloride capsules (50 mg) developed by Beijing Haibu Pharmaceutical Technology Co., Ltd. and produced by Beijing Yabao Biopharmaceutical Co., Ltd.; minocycline hydrochloride capsules (MINOMYCIN®, 50 mg) licensed and produced by Pfizer Japan Inc. were used as the reference preparation, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans.

Primary objective: To compare the differences in the extent and rate of absorption of brepirazole tablets (2 mg) provided by Beijing Haibu Pharmaceutical Technology Co., Ltd. and brepirazole tablets (2 mg, trade name: REXULTI®) certified by Otsuka Pharmaceutical Co., Ltd. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of brepirazole tablets (2 mg) provided by Beijing Haibu Pharmaceutical Technology Co., Ltd. and brepirazole tablets (2 mg, trade name: REXULTI®) certified by Otsuka Pharmaceutical Co., Ltd. in healthy adults under fasting and postprandial administration conditions.

Primary objective: This study aims to study the pharmacokinetic characteristics of agomelatine tablets (25 mg) developed by Beijing Haibu Pharmaceutical Technology Co., Ltd. and produced by Shijiazhuang Longze Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration; agomelatine tablets (Weixin®, 25 mg) produced by Les Laboratoires Servier Industrie were used as the reference preparation to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations and evaluate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation agomelatine tablets and the reference preparation agomelatine tablets (Weixin®) in healthy subjects.